March 24, 2022 6:00 am EDT

Organon launches Circle In as a new benefit for managers and employees, continuing its commitment to a ‘people first’ culture.

Organon ANZ is the first pharmaceutical company to partner with Circle In – a digital platform that helps employees and their managers support, grow and connect with caregivers in the workplace, by providing discreet support, expert advice and facilitates meaningful connections with teams and individual employees, accessible at the time when it is needed.

The on-demand content is already proving to be a useful resource for Organon’s employees and managers.  Launched just one month ago in February 2022, 35% of Organon employees have already registered on the platform and spent time interacting with the videos and articles. The most popular areas for investigation include navigating career; menopause; single parent happiness; and support for neurodiverse children.

“At Organon, we have created a People First culture, where every employee can bring their best self to work. We do this by supporting each founder – as a team member, as a parent and caregiver, and as managers of parents and caregivers, said Sophie Althans, HR Director Organon ANZ.

“It is important that we continue to evolve our employee experience, and providing resources that are relevant at each stage in our employees’ life journey at the right time is an important part of respecting and supporting the diversity of each of our founders. We hope the addition of these discreet and accessible resources to Organon’s comprehensive suite of Employee Benefits encourages honest conversations, provides thoughtful support and expert advice to help our managers and employees to maintain meaningful connections.”

About Organon

Organon (NYSE: OGN) is a global healthcare company formed through a spin-off from Merck& Co., Kenilworth, NJ, USA (NYSE: MRK) known as MSD outside of the United States and Canada, focused on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey, USA.

For more information, visit http://www.organon.com/australia and connect with us on LinkedIn.  

For more information:

MESHLIN KHOURI

meshlin.khouri@organon.com

+61 447 279 553

Forward-Looking Statement of Organon

Except for historical information herein, this news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management’s expectations about Organon’s future financial performance and prospects. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the ongoing COVID-19 pandemic and emergence of variant strains; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances; new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict its future financial results and performance; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission (SEC), including its registration statement on Form 10, available at the SEC’s Internet site (www.sec.gov).

###